CoE-Prostate Cancer Center of Excellence (USUHS)
Abstract
The CPDR is at the forefront of “cutting-edge” clinical, basic science and epidemiologic research. The emphasis is on improving diagnosis, prognosis and treatment of prostate cancer involving new modalities such as MRI guided biopsy, gene-based biomarkers, and precision medicine strategies targeting causal gene alterations in prostate cancer. The CPDR multi-center database is a unique programmatic resource, enrolling over 27,500 DoD health care beneficiaries under suspicion for prostate cancer, with longitudinal follow up to 23 years. This database continues to highlight emerging issues in prostate cancer management such e.g., treatment outcomes, racial/ethnic differences, quality of life and discovery of novel molecular prognostic markers. In light of current issues related to overtreatment of early detected prostate cancers and poorly understood biology of prostate cancer, CPDR’s long-term biospecimen banks, high-impact discoveries and collaborations are leading towards better diagnostic and prognostic molecular markers and therapeutic targets with promise in improving the management of the disease. The CPDR’s health disparity research focus has uniquely benefited from studying a prostate cancer patient cohort, with a high representation of African American men, in an equal-access military health care system. Ground-breaking studies of the most validated prostate cancer gene, ERG, in over 1,500+ patients provide the first definitive information on prostate cancer biology underscoring racial/ethnic differences with potential to enhance personalized medicine. The CPDR’s state-of-the-art research infrastructure and framework is providing education and training for over 100 next generation physicians, scientists, medical and graduate students within DoD medical institutions. Accomplishments (FY19): •Renewed infrastructure (research laboratory and CAP-certified biospecimen bank) to enhance translational research within the equal access healthcare of the DoD •Introduced new and continued successful immunotherapy clinical trials, such as, ProstAtak vaccine trial as adjuvant for localized disease and for intermediate risk prostate cancer and began autologous cellular immunotherapy for active surveillance patients •Continued the TRUMPET clinical trial for castration-resistant prostate cancers which assesses the effectiveness of treatment sequencing. Evaluated Rucaparib therapy of metastatic castration-resistant prostate cancers with BRCA 1 / 2, ATM, or CHEK mutations •Continued the Multi-disciplinary Prostate Cancer CoE/NCI clinics to determine treatment strategies based on cutting-edge clinical trials •Evaluated the predisposing germline mutation BRCA1/2 for aggressive prostate cancer for improved therapeutic stratification to enhance therapy (Petrovics et al., PCPD 2018) •Completed the assessment of new and more potent derivatives of the small molecule inhibitor ERGi-USU with potential impact on precision medicine/targeted therapy for ERG positive cancers (Mohamed, Xavier et al., Cancer Research 2018) •Provided new insights into the tumor suppressor function of LSAMP gene, frequently deleted in prostate cancers of African American men (Babcock et al., AACR 2019) •Continued focus on racial differences in prostate cancer to develop more precise urine-based biomarkers •Assessed predictors of disease progression, including: intensity of PSA screening history, comorbidity, and race-treatment interactions •Conducted multiple studies to improve clinical risk stratification and better tailored treatment by complementing pathologic patient features with molecular data Knowledge Products (FY19 - 9 Publications); Podium Presentations (FY19 - 7 Presentations); Poster Presentations (FY19 – 11 Presentations) Materiel Products (FY19) U.S. Issued Patent No.: US 10,238,639 B2, date of patent: March 26, 2019. Azophenols as ERG Oncogene Inhibitors U.S. Published Patent Application No.: US 2018/0024132 A1, date: January 25, 2018. Lipid, Protein, and Metabolite Markers for the Diagnosis and Treatment of Prostate Cancer U.S. Provisional Applications No.: 62/867/029 filed on June 26, 2019: Markers for the Diagnosis of Prostate Cancer No.: 62/779,035 filed on December 13, 2018: Genomic Rearrangements Associated with Prostate Cancer and Methods of Using the Same
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2021
- Source ID
- 75bdf00b620778573445cabd012ad47f